Abstract: Antibodies and antigen binding fragments that specifically bind to IL-7R? are disclosed. Nucleic acids encoding the antibodies and antigen binding fragments, and vectors including the nucleic acid molecules are also provided. Methods for detecting a ca cancer or a cell that expresses IL-7R? using the antibodies and antigen binding fragments are disclosed, as is the use of the antibodies and antigen binding fragments to prevent and/or treat a subject with a cancer that expresses IL-7R?, such as acute lymphoblastic leukemia.

Abstract: The present disclosure provides novel bone matrix (BM) materials, and methods for preparation and use of the demineralized bone matrix materials and compositions therefrom. The methods of preparation include the use of a closed-vessel demineralization system, as well as simple, easily reproducible process steps, and significantly shortened times for demineralization. These novel BM materials do not require the inclusion of carriers and/or delivery agents, or the addition of binders, and can be made in various forms, including a clay, putty, crush, powder, or gel. The novel BM compositions and methods disclosed herein may, illustratively, have applications in the medical field, such as in surgical bone graft applications, in the repair and/or regeneration of bone and bone-related tissue, and the like.

Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human nerve growth factor (hNGF). The formulations may contain, in addition to an anti-hNGF antibody, at least one non-ionic surfactant, at least one sugar, and acetate. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.

Abstract: Antibodies and antigen binding fragments that specifically bind to IL-7R? are disclosed. Nucleic acids encoding the antibodies and antigen binding fragments, and vectors including the nucleic acid molecules are also provided. Methods for detecting a ca cancer or a cell that expresses IL-7R? using the antibodies and antigen binding fragments are disclosed, as is the use of the antibodies and antigen binding fragments to prevent and/or treat a subject with a cancer that expresses IL-7R?, such as acute lymphoblastic leukemia.

Abstract: The present disclosure provides novel bone matrix (BM) materials, and methods for preparation and use of the demineralized bone matrix materials and compositions therefrom. The methods of preparation include the use of a closed-vessel demineralization system, as well as simple, easily reproducible process steps, and significantly shortened times for demineralization. These novel BM materials do not require the inclusion of carriers and/or delivery agents, or the addition of binders, and can be made in various forms, including a clay, putty, crush, powder, or gel. The novel BM compositions and methods disclosed herein may, illustratively, have applications in the medical field, such as in surgical bone graft applications, in the repair and/or regeneration of bone and bone-related tissue, and the like.

Abstract: Microparticles containing a core of therapeutic protein and a cortex of a biocompatible and biodegradable polymer, and methods of making and using the microparticles are provided. The extended release of a therapeutic protein from the microparticles in a physiological solution is demonstrated over an extended period of time.

Abstract: The present invention provides pharmaceutical formulations comprising an antibody that specifically binds to human delta-like ligand 4 (Dll4). The formulations may contain, in addition to an anti-Dll4 antibody, a phosphate buffer, an organic cosolvent, a disaccharide, and a salt. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months and after being subjected to thermal and other physical stress.

Abstract: Disclosed are watchbands, watchband links, and lanyards, where the watchbands comprise a band, wherein the band comprises (i) a sensor configured to generate a sensor signal representing a physical quantity, and (ii) a wireless transmitter configured to transmit a wireless signal representing the sensor signal; and a closure structure operable to close the watchband.

Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human nerve growth factor (hNGF). The formulations may contain, in addition to an anti-hNGF antibody, at least one non-ionic surfactant, at least one sugar, and acetate. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.

Abstract: Systems and methods for modifying mobile communication device settings are disclosed. The method generally includes providing a server at the headset, transmitting headset settings from the server to a client device, receiving modified settings, and implementing the modified settings.

Abstract: Methods and apparatuses for wearing state device operation are disclosed. In one example, a headset includes a sensor for detecting a headset donned state or a headset doffed state. The headset operation is modified based on whether the headset is donned or doffed.

Abstract: A printer architecture that enables a printer (or other media processing device) with an elongate foot print to be configured with media input and operator controls oriented at either a narrow end or a wide side thereof, that surface becoming the “front” of the unit. Controls and/or display(s) are mounted such that either the end or side orientation can be accommodated. The media input tray includes a separate assembly so that selection of the tray with access to end or side complements the user control panel in establishing the front of the machine. The combination of control/display mounting and oriented media tray structure integration with the print engine to establish which of the printer surfaces is considered the front allows for multiple orientations of the printer and greater flexibility to the customer.

Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (PCSK9). The formulations may contain, in addition to an anti-PCSK9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.

Abstract: A printer architecture that enables a printer (or other media processing device) with an elongate foot print to be configured with media input and operator controls oriented at either a narrow end or a wide side thereof, that surface becoming the “front” of the unit. Controls and/or display(s) are mounted such that either the end or side orientation can be accommodated. The media input tray includes a separate assembly so that selection of the tray with access to end or side complements the user control panel in establishing the front of the machine. The combination of control/display mounting and oriented media tray structure integration with the print engine to establish which of the printer surfaces is considered the front allows for multiple orientations of the printer and greater flexibility to the customer.

Abstract: The present invention provides pharmaceutical formulations comprising an antibody that specifically binds to human delta-like ligand 4 (Dll4). The formulations may contain, in addition to an anti-Dll4 antibody, a phosphate buffer, an organic cosolvent, a disaccharide, and a salt.

Abstract: Methods and apparatuses for wearing state device operation are disclosed. In one example, a headset includes a sensor for detecting a headset donned state or a headset doffed state. The headset operation is modified based on whether the headset is donned or doffed.

Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (PCSK9). The formulations may contain, in addition to an anti-PCSK9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.

Abstract: A portable, manual massage device for massaging appendage muscles, having a wrap with vertical edges and a gap defined between the vertical edges. The vertical edges have at least one anchor and are bound by at least one tension transfer member located between the vertical edges. The tension transfer members are encircled with springs between the vertical edges and enclosed by an external tension-transfer guide and an internal tension-transfer guide. The external tension-transfer guide integrally couples between an actuator and the wrap and the internal tension-transfer guide integrally couples between the anchors.

Abstract: An ink loader for a phase change ink imaging device includes an automated access control system that enables ink stick insertion based on user initiated ink load requests with reference to the operating state of the imaging device.

Abstract: Systems and methods for establishing conference calls using a headset are presented. The headset includes a wireless communications transceiver operable to form a first local wireless link with a first local telephone in communication with a first far end telephone user and a second local wireless link with a second local telephone in communication with a second far end telephone user. The headset further includes a processor operable to establish a conference call between the headset user, the first far end telephone user, and the second far end telephone user.